New research finds that the immunotherapy drug teplizumab delays the onset of type 1 diabetes by 2 years, on average, in high-risk individuals. New research has significant clinical implications, particularly for young people with a high risk of type 1 diabetes. Type 1 diabetes is an autoimmune disease affecting about 1.25 million children and adults